122226-03-3

Upstream product

• 122226-02-2 (5S,4'S,5'R)-5-<3'-<(tert-butyloxy)carbonyl>-4'-(cyclohexylmethyl)-2',2'-dimethyloxazolidin-5'-yl>-3-methylenedihydrofuran-2(4H)-one 
• 104856-05-5 (3RS,4S)-4-<(tert-butyloxy)carbonyl>-5-(cyclohexylmethyl)-3-hydroxy-1-pentene 
• 117997-58-7 tert-butyl (4S,5R)-4-(cyclohexylmethyl)-5-formyl-2,2-dimethyl-3-oxazolidinecarboxylate 
• 122226-01-1 3-<(tert-butyloxy)carbonyl>-4-(cyclohexylmethyl)-2,2-dimethyl-5-vinyloxazolidine 

Downstream Products

• 122226-04-4 (4S,5R,1'S,3'S)-3-<(tert-butyloxy)carbonyl>-4-(cyclohexylmethyl)-5-(1'4'-dihydroxy-3'-methylbutyl)-2',2'-dimethyloxazolidine 
• 127230-21-1 Toluene-4-sulfonic acid (2S,4S,5R,6S)-7-cyclohexyl-4,5-dihydroxy-2-methyl-6-(toluene-4-sulfonylamino)-heptyl ester 
• 122226-06-6 (5S,4'S,5'R)-5-<3'-<(tert-butyloxy)carbonyl>-4'-(cyclohexylmethyl)-2',2'-dimethyloxazolidin-5'-yl>-3,3-dimethyldihydrofuran-2(3H)-one 
• 127230-20-0 (2S,3R,4S,6S)-1-cyclohexyl-3,4-dihydroxy-6-methyl-2-<(p-tolylsulfonyl)amino>-7-<(p-tolylsulfonyl)oxy>heptane 
• 122226-05-5 (4S,5R,2'S,4'S)-3-<(tert-butyloxy)carbonyl>-4-(cyclohexylmethyl)-2,2-dimethyl-5-(4'-methyltetrahydrofuran-2'-yl)oxazolidine 
• 127230-19-7 (4S,5R)-4-Cyclohexylmethyl-5-((1S,3S)-1-hydroxy-4-methanesulfonyloxy-3-methyl-butyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 

Relevant academic research and scientific papers

HETEROCYCLIC PEPTIDE RENIN INHIBITORS

A renin inhibiting compound of the formula STR1 wherein X is N, O or CH; R 1 is absent or a functional group; A and L are independently selected from absent, C=O, SO 2 and CH 2 ; D is C=O, SO. sub.2 or CH 2 ; Y is N or CH; R 2 is hydrogen, loweralkyl or substituted alkyl; Z is a functional group; R 3 is loweralkyl or substituted alkyl; n is 0 or 1; and T is a mimic of the Leu-Val cleavage site of angiotensinogen; or a pharmaceutically acceptable salt, ester or prodrug thereof.

Glaucoma treatment

A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: STR1 where A is a substituent; W is CO or CHOH and U is CH2 or NR2 wherein R2 is hydrogen or loweralkyl; with the proviso that when W is CHOH then U is Ch2 ; R1 is loweralkyl, cycloalkyl methyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-hydroxybenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, 1-bezyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R3 is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)loweralkyl, (thioalkoxy)alkyl, benzyl or heterocyclic ring substituted methyl; and R4 is substituted hydroxyalkyamino.

Potent, Low Molecular Weight Renin Inhibitors Containing a C-Terminal Heterocycle: Hydrogen Bonding at the Active Site

A series of low-nanomolar renin inhibitors containing novel C-terminal heterocycles has been designed by formally cyclizing the C-terminus of a glycol-based inhibitor to the second hydroxyl.Molecular modeling suggests that the heterocyclic oxygen hydrogen

Glaucoma treatment

A method and a composition for treating or reducing and/or controlling intraocular pressure comprising administering an effective amount of a renin inhibiting compound of the formula: STR1 wherein A is a substituent; W is CO or CHOH and U is CH2/sub